Evaluation and Characteristics of a New Direct Compression Performance Excipient - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluation and Characteristics of a New Direct Compression Performance Excipient
The authors investigated the tableting properties of PanExcea MHC300G, a high-performance excipient.


Pharmaceutical Technology
Volume 35, Issue 3

Experiment

Materials. The authors obtained the following materials: PanExcea MHC300G, Avantor Performance Materials (formerly Mallinckrodt Baker); microcrystalline cellulose (102 RanQ, RanQ Pharmaceuticals & Excipients); microcrystalline cellulose (Emcocel 90, JRS Pharma); magnesium (Mg) stearate (Product No. 2256-05, Mallinckrodt Chemicals); stearic acid (Hystrene, PMC Biogenics); colloidal silica (RxCipients GL100, J. M. Huber); hydroxypropyl methylcellulose, USP grade (Pharmacoat, grade 603, SHIN-ETSU Chemical); crospovidone (Polyplasdone XL-10, International Specialty Products (ISP)); and ibuprofen (respectively, Product grade: Albemarle 20, Albemarle 40 and Albemarle 70, Albemarle; and Ibuprofen 50, BASF).

Methods. High-shear wet granulation (HSWG) of MCC (89%)/HPMC(2%)/CPVD (9%). In a 1-L stainless-steel bowl were placed 133.5 g MCC, 3.0 g HPMC and 13.5 g CPVD. The bowl was attached to a vector micro high-shear mixer/granulator (GMX.01, Vector). The dry mixture was mixed for 2 min at 870 rpm impeller speed and 1000 rpm chopper speed.

Drop by drop, 70 g of deionized water (i.e., the liquid binder) was added to the dry blend using a peristaltic pump at a dose rate of 12 g/min. During the liquid binder addition, the impeller speed was 700 rpm and the chopper speed was 1500 rpm. The wet massing time was 60 s, maintaining the same impeller and chopper speed as during liquid addition.

Following the granulation, the wet granular material was dried in a tray at 60 °C. The resulting granular material (moisture content 2.35%) was screened through a 30 mesh sieve. The yield of the granular material that passed through 30 mesh was 116.73 g (79.3 % referenced to dry starting materials and dry product).

Physical characterization. Particle-size analysis was performed using an air jet sieving instrument (Micron Air Jet Sieve, Hosokawa Micron Powder Systems). Angle of repose, aerated bulk density/tapped bulk density, and total flowability index were measured using a powder tester (Model PT-S, Hosokawa Micron Powder Systems). Particle morphology was assessed using an environmental scanning electron microscope (ESEM, XL30, FEI) using a voltage of 5 kV, spot size of 3, and SE detector. The samples were sputtered with iridium before SEM analysis (sputtering time 40 s).

Granule strength was determined using the following three methods. Method A: The particle-size distribution of 75–100 g of MHC300G was measured and the material was loaded in a 4-L V-blender (MaxiBlend, GlobePharma) and tumbled for two hours. After tumbling, the granular material was collected and analyzed again for particle-size distribution. Method B: 60 g of MHC300G were charged in a 1-L stainless-steel bowl that was attached to a vector micro high-shear mixer/granulator (GMX.01,Vector). The powder was processed by applying an impeller speed of 950 rpm and a chopper speed of 3600 rpm for 5 min. The particle-size distribution was measured before and after the high shear experiment. Method C: 100 g of MHC300G were passed through a mill (Quadro Comil model U3, Quadro Engineering) at 3000 rpm using US # 16 (1180 µm) screen.

Dilution potential of MHC300G was assessed by preparing blends of ibuprofen (IBU), MHC300G and silica. The blends were prepared in a V-blender (MaxiBlend, GlobePharma). Before blending, the powder mixture was passed through a 30 mesh sieve to break the IBU clumps. A blend containing IBU/MCC/HPMC/CPVD/silica was prepared in a similar manner. Powder characteristics as well as IBU content uniformity were analyzed for all blends.


Figure 4: Evaluation and characteristics of a new direct-compression performance excipient. Scanning electron microscope micrographs of A: MHC300G (engineered particles); B: EMB001 (engineered particles); C: EMB002 (traditional high-shear wet granulation); and D: microcrystalline cellulose. The scale bar in the images in the left column represents 100 µm, and the scale bar in the right column represents 20 µm.
Tableting studies. Unless otherwise specified, tablets were produced on an instrumented 10-station rotary tableting press (RIVA-Piccola, SMI). The tablet press was configured with 10-mm (0.3937 in.) round standard concave Tableting Specification Manual (TSM) "B" tooling. A compaction profile (i.e., the variation of tablet properties with increasing compression force at constant tablet weight and turret rotation speed) and a strain-rate study (i.e., the variation in tablet properties with turret rotation speed at constant tablet weight and compression force) were performed for powder blends containing: a) 88.75% MCC (RanQ 102), 2% HPMC, 9% CPVD, Mg stearate 0.25%; b) 99.75% PanExcea MHC300G, 0.25% Mg stearate; c) 30% ibuprofen, 61% MCC (Emcocel 90), 1.5% HPMC, 6.0% CPVD, 1% silica, 0.5% stearic acid; d) 30% ibuprofen, 68.5% MHC300G, 1% silica, 0.5% stearic acid.

The blends for the tableting studies were prepared in the following manner: all ingredients except the lubricant (Mg stearate or stearic acid), were mixed, passed through a mill (Quadro Comil model U3, Quadro Engineering) at 3000 rpm using US # 16 screen and then blended in a V-blender (MaxiBlend, GlobePharma) for 15 min at 20 rpm. The lubricant was added to the resulting mix in the V-blender and everything was blended for 3 min at 20 rpm. The final blend was discharged from the V-blender and transferred to the tableting machine.


Table I: Composition of PanExcea MHC300G, EMB001, EMB002, and EMB003 excipients.
Director Software (SMI) was used to collect and analyze the tableting data.


Table II: Bulk density, compressibility index, and Hausner ratio for various grades of microcrystalline cellulose (MCC) and coprocessed excipients containing MCC.
Tablet characterization. A friability test was performed according to the United States Pharmacopeia (USP) recommendations for friability determination of compressed, uncoated tablets (Chapter <1216>) using a tablet-friability tester (Varian Friability Tester, with Varian drum, Varian). The hardness of the tablets was measured using a tablet-hardness tester (Benchsaver series, VK 200, Varian). Tablet thickness was measured using a micrometer. Tablet-disintegration tests were performed with a disintegration system (3100, Distek) using 900 mL deionized water at 37 ± 0.5 °C.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here